Apexigen

Apexigen, Inc. was a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology. In August 2023, Pyxis Oncology, Inc. (Nasdaq: PYXS) announced the successful completion of its acquisition of Apexigen in an all-stock transaction valued at approximately $10.7 million. The transaction added a validated antibody-discovery platform, a Phase 2 candidate and a royalty stream to Pyxis Oncology, and brought the CD40 agonist sotigalimab (renamed PYX-107) into the combined company's pipeline.

Apexigen, Inc. was a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology. On August 23, 2023, Pyxis Oncology, Inc. (Nasdaq: PYXS) announced the successful completion of its acquisition of Apexigen in an all-stock transaction valued at approximately $10.7 million. The transaction added a validated antibody-discovery platform, a Phase 2 candidate and a royalty stream to Pyxis Oncology, and the combined company's platform included novel humanized antibody generation capabilities, an expanded library of linkers with improved stability, site-specific conjugation chemistries, and optimized payloads. The acquisition also brought the CD40 agonist sotigalimab, renamed PYX-107, into the combined company's pipeline.

Clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology.

• sotigalimab (PYX-107)

  A CD40 agonist described as a potentially first- and best-in-class candidate with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors; renamed PYX-107 following the acquisition.

• 2020.06.04

  Reported2020.06.04

  Apexigen appoints Gordon Ringold to its board[3]Apexigen任命Gordon Ringold为董事会成员prnewswire.com

  Apexigen announced the appointment of Gordon Ringold, Ph.D., to its Board of Directors.

• 2019.10.09

  Reported2019.10.09

  Apexigen appoints Herb Cross to its board[4]Apexigen任命Herb Cross为董事会成员prnewswire.com

  Apexigen announced that Herb C. Cross joined its Board of Directors as an independent director and would serve as chair of the board’s Audit Committee.

Read more

1. 1Pyxis Oncology Successfully Completes Acquisition of Apexigen | Pyxis Oncologyir.pyxisoncology.com
2. 2Apexigen (United States)wikidata.org
3. 3Apexigen任命Gordon Ringold为董事会成员prnewswire.com
4. 4Apexigen任命Herb Cross为董事会成员prnewswire.com
5. 5Apexigen Appoints Jakob Dupont to Board of Directorsprnewswire.com